News Releases
May 20 2003
Peregrine Clarifies Its Anti-Angiogenesis VEGF Antibody and Vascular Targeting Agents Compared to Other VEGF Antibodies
Apr 2 2003
Avid Bioservices Signs Manufacturing Supply Agreement For The Production Of Four Monoclonal Antibodies
Mar 25 2003
Peregrine Pharmaceuticals Announces Grant of Patent For Vasopermeation Enhancing Agents
Mar 17 2003
Peregrine Names Steven King As President And Chief Executive Officer
Mar 14 2003
Avid Bioservices and Inhibitex Finalize Supply Agreement for Additional cGMP Manufacturing Runs
Mar 13 2003
Overview of First International Conference on Vascular Targeting Published in Cancer Research
Mar 12 2003
Peregrine Announces Quarterly Conference Call
Feb 25 2003
Peregrine Pharmaceuticals Announces Grant Of Patent For New Anti-Angiogenic Treatments
Feb 24 2003
Peregrine Pharmaceuticals Receives FDA Approval for its Cotara(TM) Phase III Registration Trial Design for Brain Cancer
Feb 20 2003
Peregrine Pharmaceuticals Receives Additional 180-Day Grace Period from Nasdaq